预约演示
更新于：2025-04-17
Itopride Hydrochloride
盐酸伊托必利
更新于：2025-04-17
概要
基本信息
药物类型 小分子化药 |
别名 Itax、Itopride、Itopride Hydrochloridc + [19] |
作用方式 抑制剂、拮抗剂 |
作用机制 AChE抑制剂(乙酰胆碱酯酶抑制剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 日本 (1995-06-30), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H27ClN2O4 |
InChIKeyZTOUXLLIPWWHSR-UHFFFAOYSA-N |
CAS号122892-31-3 |
关联
39
项与 盐酸伊托必利 相关的临床试验TCTR20241012004
A Bioequivalence Study of Open-label, Randomized, Single Oral Dose, Two-way Crossover Design of Generic Itopride Hydrochloride 50 mg Film Coated Tablets and Reference Product (Ganaton) in Healthy Thai Subjects under Fasting Conditions
CTR20241978
盐酸伊托必利片在健康受试者中单剂量、随机、开放、空腹两周期/餐后四周期、两序列、交叉设计的生物等效性试验
NCT06217393
Randomized Multicentre Open-label Study to Investigate the Non-inferiority of Itopride Hydrochloride 150mg Once Daily Versus Itopride Hydrochloride 50 mg Thrice Daily in Subjects With Functional (Non-ulcer) Dyspepsia or Chronic Gastritis
100 项与 盐酸伊托必利 相关的临床结果
登录后查看更多信息
100 项与 盐酸伊托必利 相关的转化医学
登录后查看更多信息
100 项与 盐酸伊托必利 相关的专利（医药）
登录后查看更多信息
412
项与 盐酸伊托必利 相关的文献（医药）2025-01-02Expert Opinion On Drug Safety
Risk of drug-induced delirium in older patients- a pharmacovigilance study of FDA adverse event reporting system database
Article
作者: Li, Jiayu ; Zhou, Ying ; Jia, Boying ; Zhou, Shuang ; Wan, Liyan ; Cui, Yimin
BACKGROUND:
Drug-induced delirium is known risk factors associated with increased morbidity and mortality in older patients. The objective was to evaluate the risk of drug-related delirium in older patients based on the FDA Adverse Event Reporting System (FAERS).
RESEARCH DESIGN AND METHODS:
Delirium reports in older patients (age ≥65) extracted from the FAERS database using Open Vigil 2.1. The reported odds ratio and the proportional reported ratio were calculated to detect the adverse reaction signal of delirium. Combined with published evidence, suspected drugs were categorized as known, possible, or new potential delirium-risk-increasing drugs.
RESULTS:
Of the 130,885 reports (including 28,850 delirium events and 1,857 drugs) analyzed for this study, 314 positive signal drugs were detected. Positive signal drugs are mainly concentrated on the drug of nervous system, cardiovascular system , alimentary tract and metabolism and anti-infectives for systemic use. Of the positive signal drugs, 26.11% (82/314) were known delirium-risk increasing drugs, 44.90% (141/314) were possible and 28.98% (91/314) were new potential.
CONCLUSION:
Drug-induced delirium risk is prevalent in older patients, according to the FAERS. The risk level of drug-induced delirium should be taken into account to optimize drug therapy in clinical practice.
2025-01-01Therapeutic Advances in Gastroenterology
Itopride in functional dyspepsia: open-label, 1-year treatment follow-up of two multicenter, randomized, double-blind, placebo-controlled trials
Article
作者: Tack, Jan ; Broeders, Bert ; Talley, Nicholas J.
Background::
Functional dyspepsia (FD) is common but few efficacious therapies exist. Itopride, a prokinetic, acts via dopamine D2 receptor antagonism and acetylcholinesterase inhibition, and is now approved in Japan, Mexico, and Europe for FD. However, long-term efficacy and safety data have not been published.
Objective::
To evaluate the long-term safety and potential effectiveness of itopride.
Design::
A long-term open-label drug effectiveness study.
Methods::
Males and females, 18–65 years, with FD (Rome II) and the absence (by upper endoscopy) of any relevant structural disease were recruited. After the double-blind treatment phase, patients were treated in an open-label extension phase.
Results::
A total of 798 patients were included in these two open-label trials and received at least one dose of study medication; 551 patients (69.0%) completed 6 months of treatment, and 294 patients (36.8%) completed a 12-month period. Response rates based on the global physician assessment were 61.7%, 64.8%, 69.0 %, 69.1%, 70.1%, 73.1%, and 77.9% at weeks 8, 16, 24, 32, 40, 48, and 52, respectively. Compliance was above 95%. The safety and tolerability profiles were as expected, with the majority of adverse events being gastrointestinal. Prolactin elevations occurred in 3% of the cases but were not clinically significant. No ECG changes were identified.
Conclusion::
In this population, itopride, given for up to 12 months, was safe, and up to two-thirds appeared to maintain symptom benefit.
Trial registration::
NCT00110968 and NCT00112203.
2025-01-01ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Clinical Trial: Treatment of Functional Dyspepsia According to Subtype Compared With Empirical Proton Pump Inhibitor
Article
作者: Hian, Wen Xuan ; Mahadeva, Sanjiv ; Khoo, Stanley ; Chuah, Kee Huat ; Khoo, Xin Hui ; Natarajan, Vicraman ; Jubri, Nurhidayah Binti Mohammad ; Loo, Qing Yuan ; Panirsheeluam, Sarala
ABSTRACT:
Background:
International guidelines recommend contrasting initial treatment strategies for functional dyspepsia (FD).
Aims:
To evaluate the efficacy and safety of treatment according to subtypes, compared with empirical proton pump inhibitor (PPI), in the initial treatment of FD.
Methods:
We performed a single‐blinded, randomised controlled trial of adults with FD. In the intervention group (treatment according to subtype), patients were categorised into epigastric pain syndrome (treatment esomeprazole); postprandial distress syndrome (PDS; treatment itopride) and overlap (treatment itopride, maintain, add/or switch to esomeprazole at week 4). The control group received esomeprazole only. The primary efficacy outcome was the assessment of global symptom improvement (primary end point: best two points from the 7‐point Likert scale) over 8 weeks. Secondary outcomes included assessment of the change in nine individual upper gastrointestinal symptoms, quality of life (Short‐Form Nepean Dyspepsia Index) and adverse events.
Results:
We randomised 180 patients (median age: 50; 68.7% female 56.7% PDS) 1:1 into intervention and control arms. The percentage of patients achieving the primary efficacy outcome were 74.4% and 72.2%, respectively (p = 0.74). The improvement of individual symptoms in both groups were similar. The SF‐NDI improved after treatment in both groups (p < 0.001) but there was no significant difference in the degree of change between groups. Rates of adverse events between groups were similar at week 8.
Conclusion:
Initial treatment of FD according to subtype was not more effective than empirical PPI alone for up to 8 weeks. Further multicentre studies, with a larger sample size, are recommended to validate these findings.Trial Registration: ClinicalTrials.gov identifier: NCT04918017
100 项与 盐酸伊托必利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃肠道疾病 | 印度 | 2003-01-20 | |
| 慢性胃炎 | 日本 | 1995-06-30 | |
| 心脏衰竭 | 中国 | - | - |
| 高血压 | 中国 | - | - |
| 恶心 | - | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 餐后窘迫综合征 | 临床3期 | 亚美尼亚 | 2024-02-28 | |
| 餐后窘迫综合征 | 临床3期 | 马来西亚 | 2024-02-28 | |
| 餐后窘迫综合征 | 临床3期 | 菲律宾 | 2024-02-28 | |
| 餐后窘迫综合征 | 临床3期 | 泰国 | 2024-02-28 | |
| 餐后窘迫综合征 | 临床3期 | 越南 | 2024-02-28 | |
| 胃灼热 | 临床3期 | 美国 | 2006-10-01 | |
| 肠道疾病 | 临床3期 | 美国 | 2005-11-01 | |
| 腹部膨胀 | 临床3期 | 加拿大 | 2004-07-01 | |
| 消化不良 | 临床3期 | 德国 | 2000-12-01 | |
| 便秘型肠易激综合征 | 临床2期 | 巴基斯坦 | 2008-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | 鹽製選願糧齋鏇鑰鏇構(廠鑰鑰鑰鑰積製觸夢遞) = 繭鹽選鏇繭襯鑰衊願選 艱艱築憲繭願遞糧鏇選 (鬱顧願夢餘鹽顧齋獵壓, 25) | - | 2018-10-01 | ||
鹽製選願糧齋鏇鑰鏇構(廠鑰鑰鑰鑰積製觸夢遞) = 淵遞構鬱繭襯醖選淵構 艱艱築憲繭願遞糧鏇選 (鬱顧願夢餘鹽顧齋獵壓, 32) | |||||||
N/A | - | 鏇蓋膚範糧鹹積簾膚艱(選繭醖鏇築糧餘淵觸積) = 艱鏇蓋餘願範築範夢齋 憲衊繭醖窪醖構窪廠廠 (製憲蓋簾壓餘選築簾廠 ) 更多 | - | 2005-06-01 | |||
Placebo | 鏇蓋膚範糧鹹積簾膚艱(選繭醖鏇築糧餘淵觸積) = 鬱範淵築齋網願壓夢衊 憲衊繭醖窪醖構窪廠廠 (製憲蓋簾壓餘選築簾廠 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和Eureka LS聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用